| Literature DB >> 29723249 |
Tadesse Melaku Abegaz1, Eshetie Melese Birru2, Gashaw Binega Mekonnen1.
Abstract
BACKGROUND: There was a paucity of data on the magnitude of potentially inappropriate prescriptions (PIPs) among Ethiopian elderly cardiovascular patients.Entities:
Mesh:
Year: 2018 PMID: 29723249 PMCID: PMC5933717 DOI: 10.1371/journal.pone.0195949
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sociodemographic and clinical characteristics of respondents 2016/2017 (n = 239).
| Variable | Value |
|---|---|
| Age (mean ±SD) | 72.52 ±7.7 |
| Sex(males) | 123 (51.50) |
| Residence (urban) | 127 (53.10) |
| Comorbidities (n = 118) | |
| Respiratory disorders | 32 (27.12) |
| Rheumatic and cardio-myopathy | 25 (20.34) |
| Kidney disease | 24 (21.19) |
| Thyroid disorder | 19 (16.10) |
| Diabetes | 18 (15.25) |
| Diagnosis (n = 239) | |
| HTN+ Stroke | 69(28.87) |
| Heart failure | 88(36.82) |
| Atrial fibrillation | 13(5.44) |
| Peripheral arterial disease | 19(7.95) |
| DVT | 11(4.60) |
| HTN | 19(7.95) |
| AF +stroke | 8(3.35) |
| AF+CHF | 12(5.02) |
| Hospital stay(mean ±SD) | 16.99±4.51 |
| number of medications during hospital stay(mean ±SD) | 3.97±1.55 |
| number of medications at discharge (mean ±SD) | 2.91±0.99 |
| Procured medications (yes) | 239(100) |
| Taking medication (yes) | 239(100) |
| OTC medication (no) | 239(100) |
Abbreviation: AF, Atrial fibrillation; CHF, Congestive heart failure; DVT, Deep vein thrombosis; HPN, Hypertension; OTC, Over the counter medication; SD, Standard deviation
IPs based on individual STOPS/START criteria among older CVPs in 2016/2017 (n = 221).
| PIPs | Frequency n (%) |
|---|---|
| | 106(48%) |
| Any medication prescribed without any indication | 28(12.7%) |
| Digoxin | 21(9.5) |
| Unfractionated heparin | 3(1.4) |
| Amlodipine | 5(2.3) |
| Any medication prescribed beyond the recommended duration | 0(0.00) |
| Any duplicate medication | 2(0.9) |
| Digoxin for heart failure with normal systolic ventricular function | 3(1.4) |
| verapamil or diltiazem with class three or four heart failure | 0(0.00) |
| Beta-blocker with verapamil or diltiazem | 0(0.00) |
| beta blocker with bradycardia | 5(2.3) |
| Loop diuretics with dependent ankle edema | 5(2.3) |
| Loop diuretic for treatment of hypertension in urinary incontinence | 3(1.4) |
| Loop diuretic as first-line treatment for hypertension | 0(0.00) |
| Thiazide diuretic with current electrolyte imbalance | 0(0.00) |
| Aspirin in peptic ulcer patients without anti-acid | 9(4.1) |
| Spironolactone with K-sparing medications without checking the level of K+ | 20(9) |
| Aspirin with VKA in patients with chronic atrial fibrillation | 31(14) |
| ACEIs or Angiotensin Receptor Blockers in patients with hyper-Kalema. | 0(0.00) |
| PPOs | 115(52%) |
| VKA or direct thrombin inhibitors in the presence of chronic AF | 12(10.43) |
| ACEIs with systolic heart failure/coronary artery disease | 32(14.5) |
| Aspirin in the presence of chronic atrial fibrillation. | 0(0.00) |
| Antiplatelet to coronary, cerebral or peripheral vascular disease. | 5(2.3) |
| Antihypertensive therapy where BP> 160/90mmHg | 29(12.15) |
| Statin therapy with coronary, cerebral or peripheral vascular disease | 7(3.16) |
| Beta-blocker with ischemic heart disease | 0(0.00) |
| Appropriate beta-blocker with stable systolic heart failure | 30(13.1) |
| Total IPs | 221 (100%) |
Fig 1The top ten common drugs associated with IP among CVPs admitted to UOGH, 2016/2017.
IPs in elderly CVPs presented with different diagnosis at UOGH 2016/17: One way ANOVA test.
| Diagnosis | Mean(SD) | F-test | P-value |
|---|---|---|---|
| HTN | 1.68±1.416 | 5.718 | <0.001 |
| AF+ stroke | 1.63±0.518 | ||
| HF | 1.48±1.134 | ||
| AF | 1.08±1.188 | ||
| DVT | 0.09±0.302 | ||
| PAD | 0.32±0.478 | ||
| HF+ stroke | 1.17±1.111 |
Factors affecting IPs in elderly CVPS attending UOGH 2016/2017.
| Variables | IP status of patients | COR [95% CI] | AOR [95% CI] | ||
|---|---|---|---|---|---|
| Yes (147) | No (92) | ||||
| Age (mean ±SD) | 72.26±7.583 | 72.95 ±7.907 | 0.989[0.956–1.022] | 1.011[0.970–1.050] | |
| Sex | |||||
| Females | 65(27.2) | 51(21.3) | 1 | 1 | |
| Males | 82 (34.3) | 41(17.2) | 0.637[0.377–1.077] | 0.598 | [0.333–1.075] |
| Hospital stay(mean ±SD) | 15.77 ±4.111 | 17.26 ±4.856 | 1.11[1.041–1.180] | 1.086 | [1.016–1.160] |
| Comorbidities | |||||
| Yes | 87(36.4) | 31(13) | 2.853[1.657–4.912] | 3.127[1.706–5.733] | |
| No | 60(25.1) | 61(25.5) | 1 | 1 | |
| number of medications during | 3.13±0.909 | 2.83±1.145 | 1.378[1.149–1.652] | 0.751 | [0.482–1.170] |
| hospital stay | |||||
| number of medications at | 3.10 ±1.12 | 2.61±0.87 | 1.662[1.258–2.196] | 1.924 | [1.217–3.041] |
| discharge | |||||
*Significant at <0.05
**significant at <0.01